‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include WSOC TV, insightnews.com.au, USA Today and WSJ. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.
Quick answers
Why is "‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taki" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (8)
- Patients sue GLP-1 makers over sudden loss of vision NewsNation · 14h ago
- What GLP-1 users should know about the potential risk of a rare type of vision loss ABC News - Breaking News, Latest News and Videos · 14h ago
- Hundreds of lawsuits filed against some GLP-1 Makers over vision loss Yahoo · 14h ago
- Patients sue GLP-1 makers over risk of blindness WSOC TV · 14h ago
- Vision loss concerns spark US lawsuits as Australian bodies issue advice on GLP-1 drugs insightnews.com.au · 14h ago
- Are GLP-1s causing blindness? What we know about rare cases USA Today · 14h ago
- Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss WSJ · 14h ago
- ‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1 Boston 25 News · 14h ago
Topics
Related trends
The company behind a new GLP-1 pill is betting $6.5 billion on Houston
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Millions of parents are taking GLP-1s. How should they talk to their kids about it?
As millions of parents use GLP-1 medications, discussions around childhood obesity and weight loss drugs take center stage in families.
When Weight Loss Isn’t the Goal of Taking a GLP-1
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Woman in her 30s tests positive for West Nile Virus, marking eighth human case in Massachusetts
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Novo Nordisk (NVO) and Eli Lilly (LLY)’s Weight-Loss Drugs Still Work at Smaller Doses, Study Finds
Recent studies indicate that popular weight-loss treatments manufactured by Novo Nordisk and Eli Lilly retain efficacy at reduced doses.